New biomedical project starts construction in WND

A ground-breaking ceremony of the third phase of STA Pharmaceutical Co Ltd's research and development center and production base for new drug preparations is held in Wuxi National Hi-tech District on Jan 25. [Photo/wnd.gov.cn]

Construction started on the third phase of STA Pharmaceutical Co Ltd's research and development center and production base for new drug preparations in Wuxi National Hi-tech District on Jan 25.

According to STA Pharmaceutical Co Ltd, the first phase of the project has been put into operation to provide global customers with new drug preparation commercialization services. The second phase started construction last January and will start operation in April. The third phase of the project is expected to be put into operation in 2023.

After the whole project is put into operation, STA Pharmaceutical Co Ltd will own an integrated platform for new drug preparation R&D and production, including leading high-enclosed workshops for solid and sterile preparation.

A plan map of the project. [Photo/wnd.gov.cn]

Cui Rongguo, deputy director of Xinwu district of Wuxi, said that in 2020, WND's industrial scale of biomedical industry exceeded 60 billion yuan ($9.26 billion), accounting for half of the city's total amount. WND also released a three-year plan to promote the development of its biomedical industry.

Chen Jinling, senior vice director of STA Pharmaceutical Co Ltd, thanked WND for the long-term support and quality services provided for their business development. Chen said that the company will work to build WND into a new hub for global pharmaceutical R&D and production service platforms.

STA Pharmaceutical Co Ltd is a subsidiary of WuXi AppTec. It owns multiple R&D and production bases around the world to serve the life sciences industry with capabilities and platforms to develop chemical innovation drugs.